An elastase-responsive "plug-and-play" quercetin-loaded engineered extracellular vesicle platform anchored with anti-PRDX1 antibody for severe acute pancreatitis therapy

Key Points

• Extracellular vesicles effectively deliver quercetin, targeting severe acute pancreatitis therapies.
• Key evidence includes a significant response to elastase release, enhancing drug delivery efficiency.
• The approach utilizes engineered extracellular vesicles, anchored with an anti-PRDX1 antibody for specificity.
• The findings suggest a new treatment strategy, paving the way for further investigations in pancreatitis therapy.